AI-generated from publicly available materials.Clarivate has enhanced its Cortellis portfolio with advanced agentic AI capabilities, aiming to transform decision-making in drug development for life sciences organizations.
This initiative focuses on integrating AI into existing workflows to streamline research and development processes. By doing so, Clarivate enables R&D teams to expedite drug discovery, enhance safety assessments, and make informed portfolio decisions more swiftly. The Cortellis suite combines reliable life sciences data with expert curation and AI to facilitate actions across the drug development lifecycle.
Key advancements include improved decision-making in drug discovery through natural language interactions that allow researchers to navigate complex datasets efficiently. The OFF-X platform has also been upgraded to support proactive safety assessments, enabling teams to identify potential risks earlier in the development process. Additionally, the Cortellis Competitive Intelligence tools now provide strategic insights more rapidly, converting lengthy analyses into actionable intelligence.
This evolution signifies a shift from merely providing insights to enabling actionable workflows, enhancing the overall productivity and efficacy of life sciences teams. As organizations increasingly rely on data-driven decisions, these innovations position Clarivate as a pivotal player in the life sciences sector, fostering faster and more accurate decision-making in high-stakes environments.